Physician profile
Pierre E Raad
NPI 1407877418
$715.34
in general payments reported to CMS, 2019-2025
14 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2021: $16.47 · 2022: $179 · 2023: $75.86 · 2024: $99.30 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $141.65 | 2019-2025 | Bexsero, Penmenvy |
| Sanofi Pasteur INC. | $107.20 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $85.65 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $74.16 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $68.82 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $63.35 | 2022 | |
| Collegium Pharmaceutical, INC. | $57.82 | 2025 | Jornay Pm |
| Neurelis, INC. | $19.56 | 2025 | Valtoco |
| Novo Nordisk INC | $18.75 | 2025 | Wegovy |
| Biomarin Pharmaceutical INC. | $18.25 | 2023 | Voxzogo 1.2mg |
| Takeda Pharmaceuticals U.S.A., INC. | $17.44 | 2022 | |
| Boston Scientific Corporation | $16.36 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.33 | 2019 | |
| Genentech USA, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Raad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.